Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

Cancer Gene Therapy volume 12, pages 109–115 (2005)Cite this article

Abstract

Local and locoregional administration of adenovectors expressing the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene has been demonstrated to be useful in treating established tumors in animals. Moreover, expression of the TRAIL gene from the human telomerase reverse transcriptase (hTERT) promoter can be used to prevent possible liver toxicity of the TRAIL gene. However, it remains unknown whether systemic administration of the TRAIL-expressing adenovector can be used for cancer therapy. Here, we showed that a combination of TRAIL gene therapy and gemcitabine, the first-line chemotheraphy agent for pancreatic cancer, had a synergistic effect on the induction of apoptosis in human pancreatic cancer cell lines in vitro. Systemic administration of an adenovector that contains an insertion of integrin-binding motif argine-glycine-aspartate (RGD) in the HI loop of the adenoviral fiber protein and expresses the human TRAIL gene from the hTERT promoter (designated Ad/TRAIL-F/RGD) suppressed the growth of human pancreatic tumor cells inoculated in the liver of nu/nu nude mice. Furthermore, Ad/TRAIL-F/RGD in combination with gemcitabine suppressed the tumor growth of pancreatic cancer in the liver more than did treatments consisting of each agent alone. No obvious liver toxicity was detected in any of the treatment groups. Our results suggest that TRAIL gene therapy in combination with gemcitabine might be a useful therapeutic approach for treating metastatic pancreatic cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Blaszkowsky L . Treatment of advanced and metastatic pancreatic cancer. Front Biosci. 1998;3:E214–E225.

    Article  CAS  PubMed  Google Scholar 

  2. Shi X, Friess H, Kleeff J, et al. Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology. 2001;1:517–524.

    Article  CAS  PubMed  Google Scholar 

  3. Kulke MH . Metastatic pancreatic cancer. Curr Treat Option Oncol. 2002;3:449–457.

    Article  Google Scholar 

  4. Tsai JY, Iannitti DA, Safran H . Combined modality therapy for pancreatic cancer. Seminar Oncol. 2003;30:71–79.

    Article  CAS  Google Scholar 

  5. Bardeesy N, DePinho RA . Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909.

    Article  CAS  PubMed  Google Scholar 

  6. Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol. 1998;5:681–688.

    Article  CAS  PubMed  Google Scholar 

  7. Pearson AS, Bouvet M, Evans DB, et al. Gene therapy and pancreatic cancer. Front Biosci. 1998;3:E230–E237.

    Article  CAS  PubMed  Google Scholar 

  8. Katz MH, Spivack DE, Takimoto S, et al. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol. 2003;10:762–772.

    Article  PubMed  Google Scholar 

  9. Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000;60:5359–5364.

    CAS  PubMed  Google Scholar 

  10. Lin T, Gu J, Zhang L, et al. Targeted expression of green fluorescent protein/Tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effect on primary human hepatocytes. Cancer Res. 2002;62:3620–3625.

    CAS  PubMed  Google Scholar 

  11. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706–9713.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 1997;71:8221–8229.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Jacob DA, Davis JJ, Zhu H, et al. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the hTERT promoter. Clin Cancer Res. 2004;10:3535–3541.

    Article  CAS  PubMed  Google Scholar 

  14. Fang B, Roth JA . The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther. 2003;5:475–482.

    CAS  PubMed  Google Scholar 

  15. Fang B, Ji L, Bouvet M, et al. Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem. 1998;273:4972–4975.

    Article  CAS  PubMed  Google Scholar 

  16. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001;61:3330–3338.

    CAS  PubMed  Google Scholar 

  17. Kavolius J, Fong Y, Blumgart LH . Surgical resection of metastatic liver tumors. Surg Oncol Clin North Am. 1996;5:337–352.

    Article  CAS  Google Scholar 

  18. McCarter MD, Fong Y . Metastatic liver tumors. Seminar Surg Oncol. 2000;19:177–188.

    Article  CAS  Google Scholar 

  19. Hosch SB, Steffani KD, Scheunemann P, et al. Micrometastases from HBP malignancies and metastatic cancer. J Hepato-Biliary-Pancreatic Surg. 2002;9:583–591.

    Article  Google Scholar 

  20. Charnsangavej C, Loyer EM, Iyer RB, et al. Tumors of the liver, bile duct, and pancreas. Curr Prob Diagn Radiol. 2000;29:69–107.

    CAS  Google Scholar 

  21. Paulson EK . Evaluation of the liver for metastatic disease. Semin Liver Dis. 2001;21:225–236.

    Article  CAS  PubMed  Google Scholar 

  22. Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999;59:734–741.

    CAS  PubMed  Google Scholar 

  23. Lin T, Zhang L, Davis JJ, et al. Combination of TRAIL gene therapy and chemotherapy enhanced anti-tumor and anti-metastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther. 2003;8:441–448.

    Article  CAS  PubMed  Google Scholar 

  24. Cuello M, Ettenberg SA, Nau MM, et al. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gyn Oncol. 2001;81:380–390.

    Article  CAS  Google Scholar 

  25. Liu W, Bodle E, Chen JY, et al. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Resp Cell Mol Biol. 2001;25:111–118.

    Article  CAS  Google Scholar 

  26. Matsuzaki H, Schmied BM, Ulrich A, et al. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res. 2001;7:407–414.

    CAS  PubMed  Google Scholar 

  27. Xu ZW, Kleeff J, Friess H, et al. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res. 2003;23:251–258.

    CAS  PubMed  Google Scholar 

  28. Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 2000;60:847–853.

    CAS  PubMed  Google Scholar 

  29. Yamanaka T, Shiraki K, Sugimoto K, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology. 2000;32:482–490.

    Article  CAS  PubMed  Google Scholar 

  30. Gibson SB, Oyer R, Spalding AC, et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol. 2000;20:205–212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Yoon SK, Armentano D, Wands JR, et al. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gene Ther. 2001;8:573–579.

    Article  CAS  PubMed  Google Scholar 

  32. Croyle MA, Chirmule N, Zhang Y, et al. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 2001;75:4792–4801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. O'Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10:1349–1358.

    Article  CAS  PubMed  Google Scholar 

  34. Siemens DR, Elzey BD, Lubaroff DM, et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol. 2001;166:731–735.

    Article  CAS  PubMed  Google Scholar 

  35. Yotnda P, Chen DH, Chiu W, et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002;5:233–241.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Gayle Nesom for editorial review and Jesse Null and Alma Vega for assistance in preparing the manuscript. This article represents partial fulfillment of the requirements for the PhD degree for JJD. This work was supported in part by the National Cancer Institute/National Institute of Health (RO1 CA 092487-01A1, RO1 CA 098582-01A1 (to BF) and Core Grant CA 16672) and by Lockton Grant Matching Program.

Author information

Authors and Affiliations

  1. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center Houston, Texas, 77030, USA

    Dietmar Jacob, John J Davis, Lidong Zhang, Hongbo Zhu, Fuminori Teraishi & Bingliang Fang

  2. Program in Gene Therapy and Virology, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, 77030, USA

    John J Davis & Bingliang Fang

Authors
  1. Dietmar Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John J Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lidong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hongbo Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fuminori Teraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bingliang Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bingliang Fang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacob, D., Davis, J., Zhang, L. et al. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 12, 109–115 (2005). https://doi.org/10.1038/sj.cgt.7700773

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700773

Keywords

This article is cited by

Search

Advanced search

Quick links